AnalystsMartin FanMartin Fan's Stock Forecasts
AnalystsMartin Fan
Sectors:
Industries:
Analyst Ranking
Top 10%
#506 out of 5254 analysts
Average Return
+77.07%
Win Rate
74%17 out of 23
Risk vs Reward
Poor
Good
Martin Fan's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Oruka Therapeutics IncORKA | +628.54% | $9.46 | $68.92 | 2025-05-15 - 2026-04-17 | Buy |
Anaptysbio IncANAB | +231.42% | $20.37 | $67.51 | 2025-08-07 - 2026-04-17 | Buy |
Anaptysbio IncANAB | +211.11% | $21.70 | $67.51 | 2025-05-01 - 2026-04-17 | Buy |
Aclaris Therapeutics IncACRS | +201.42% | $1.41 | $4.25 | 2025-05-28 - 2026-04-17 | Buy |
Anaptysbio IncANAB | +120.48% | $30.62 | $67.51 | 2025-09-30 - 2026-04-17 | Buy |
Martin Fan Analyst Color
Get additional color on Martin Fan's coverage of popular stocks
Martin Fan's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Oruka Therapeutics IncORKA | 4 | Buy | $85.00 | +23.33% | Maintains | 5 days ago |
Sana Biotechnology IncSANA | 3 | Buy | $7.00 | +98.86% | Maintains | 6 days ago |
Vor Biopharma IncVOR | 2 | Hold | $15.00 | -9.58% | Maintains | 20 days ago |
Aclaris Therapeutics IncACRS | 2 | Buy | $8.00 | +88.24% | Reiterates | 20 days ago |
Nektar TherapeuticsNKTR | 1 | Hold | $70.00 | -17.51% | Initiates Coverage On | a month ago |
Anaptysbio IncANAB | 6 | Buy | $75.00 | +11.09% | Maintains | a month ago |
Cartesian Therapeutics IncRNAC | 2 | Buy | $38.00 | +439.77% | Reiterates | a month ago |
Zura Bio LtdZURA | 1 | Buy | $15.00 | +158.18% | Initiates Coverage On | 2 months ago |
Zenas Biopharma IncZBIO | 2 | Buy | $45.00 | +106.23% | Reiterates | 4 months ago |
Imagenebio IncIMA | 1 | Sell | $2.00 | -66.10% | Assumes | 5 months ago |
Artiva Biotherapeutics IncARTV | 2 | Buy | $23.00 | +83.27% | Maintains | 6 months ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.